This clinical trial is focused on patients with End Stage Renal Disease (ESRD) who are receiving hemodialysis. The study is investigating a new treatment called MK-2060, which is a solution given through an intravenous infusion. The purpose of the study is to see if MK-2060 can help prevent a condition known as arteriovenous graft thrombosis. This condition occurs when a blood clot forms in a graft used for dialysis, which can cause problems with the dialysis process.

Participants in the study will receive either MK-2060 or a placebo. The study will compare the time it takes for the first occurrence of arteriovenous graft thrombosis between the two groups. The trial will also monitor the number of participants who experience any side effects, including major or clinically relevant bleeding events, and those who stop the study due to side effects. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving MK-2060 or the placebo, to ensure unbiased results.

The study will take place over a period of time, with participants receiving treatment and being monitored for any changes in their condition. The goal is to determine if MK-2060 is effective and safe for patients with ESRD undergoing hemodialysis. This research could potentially lead to better management of arteriovenous graft thrombosis in these patients, improving their overall treatment experience.